Gils background: Stanford, PhD in Genetics, double major in Economics, Molecular Biology. Whiz kid? ? (GIL) I take my personal money and invest it in the company every opportunity I get because I believe we're an extraordinary investment opportunity.
2) we've gone on to show that we can take cells from an individual healthy donor and produce banks that have the potential to yield the equivalent of millions of clinical doses of MultiStem
3) announced that we've completed the first couple of dosing groups in our Stroke clinical trial. Partnership with Pfizer, with IBD (inflammatory bowel diseas
), and the Stroke program, Pfizer Regenerative Medicine
4) Time frame may not to far away- In summary, ATHX has a unique cell therapy program that reads out potential stock moving data in 2013 and 2014, and they have multiple, meaningful potential partnerships besides Pfizer on the horizon.
IF we get some good data from Pfizer to take it into another indication such as Crohn's disease or Stroke data next year, the value creation is less than 18 months of wait for you.
5) THE market to bearish on Cell technology- people don't recognize that there are a growing number of cell therapy based products that are already on the market today and that are being used clinically and commercially.
6) Pfizer, Shire, Johnson & Johnson, Roche, and quite a few other companies have started to make strategic bets in the area because they recognize that this is an area that may actually transform medicine in a lot of different ways.
7) our current phase two trial and treating Ischemic stroke patients. In other cases, we're doing it with a partner, like our clinical trial with Pfizer, which we expect to have results on sometime in the latter half of this year
8) MultiStem can be manufactured at scale, has a long shelf life in a vial or IV. bag, and can be administered by an IV, syringe, or catheter as needed. Pharmaceutical companies, and most physicians for that matter, want something that can be delivered simply and efficiently at the point of care with a minimum amount of hassle or minimal amount of trouble. They also would prefer something that has been fully characterized from a safety and potency standpoint.
9) data SUGGEST- if MultiStem is administered even days after a stroke has occurred, very powerful and durable therapeutic benefits are seen -- many animals saw virtually complete recovery. Think about what that might mean from a clinical perspective and a commercial perspective. Typically, hospitalization, physical therapy, occupational therapy, and rehabilitation costs, as well as permanent institutional care and home care costs, can be an enormous financial burden for patients and their families - let alone the quality of life impact.
10) Numbers and market- Over the next few years in the U.S., for example, we will see an 80% increase in the number of people over the age of 65 -- exactly the segment of the population most susceptible to stroke.
But just take the current two million stroke patients a year number, and begin by recognizing the current cost of care for stroke patients is enormously high and it doesn't really help many of them get better.
If you assume that we are only reaching half of the stroke patients in that two million a year number, you're talking about a million patients a year and you're talking about $15,000 to $20,000 per patient. That creates a $15 to $20 billion a year market opportunity